Background: The aim of this prospective placebo-controlled pilot study was to evaluate short-term effects of a\nmouthrinse containing aluminium triformate (ATF) on gingival inflammation and plaque formation in periodontal\npatients who are in the maintenance phase. ATF has styptic (astringent) and anti-inflammatory effects.\nMethods: Forty non-smoking periodontal patients with modified sulcus bleeding index (MSBI) �40 % were randomly\ndivided into two groups. The participants received a masked mouthrinse (ATF or placebo) and were instructed with the\nrinsing protocol of 3 daily rinses during 30 s for 7 days. One blinded investigator (CE) performed all clinical examinations.\nThe primary outcome was reduction in gingival inflammation as measured by MSBI. The secondary outcomes were\nreduction of the amount of plaque as measured by plaque index (PI) and approximal plaque index (API) and the\noccurrence of side effects. The patients were evaluated at the start and the end of the rinsing period, including the\ncompliance of the patients.\nResults: MSBI was reduced in both groups compared to baseline, but the ATF group showed significantly more\nreduction in MSBI compared to the placebo group (ATF: 17.6 %, placebo: 7.6 %, p = 0.035). ATF and placebo had no\neffects on dental plaque. Patients reported ATF mouthrinse not to have side effects other than oral sensation, whereas\ncompliance of the patients was good. Almost all patients in the ATF group reported reduction of gum bleeding after\n1 week of rinsing with ATF.\nConclusions: This short-term pilot clinical trial is a firm basis to design a long-term controlled clinical trial to show\nwhether ATF helps to inhibit further periodontal breakdown in maintenance patients with high MSBI.
Loading....